HOME > Business Wire > Article
Fujita Health University and BostonGene Expand Access to Genomic Cancer Testing with Tumor Portrait™ at Haneda Clinic
BostonGene’s advanced molecular and immune profiling delivers detailed cancer insights, enabling evidence-based treatment decisions and improving cancer care standards
TOKYO & WALTHAM, Mass.--( BUSINESS WIRE )-- Fujita Health University and BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients utilizing the BostonGene Tumor Portrait™ test.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241022832759/en/
The comprehensive genomic test supports oncologists by identifying actionable mutations, microenvironment properties and biomarkers of response by integrating DNA and RNA sequencing results with patient clinical profiles, selected treatment options and available clinical trials into one simple report.
Building on the foundational research first published in Cancer Cell in 2021, the Tumor Portrait™ test reveals the key drivers of each tumor, including cancer-associated genetic mutations, immune system interactions, biomarkers predicting response to various therapies and personalized treatment recommendations. The Tumor Portrait™ is an award winning, CLIA-certified, CAP-accredited, approved clinical test widely used by leading academic and community oncologists across the U.S.
At Fujita Health Haneda Clinic, patients also have access to cutting-edge therapies, including oncological gene therapies that use genetic analysis to provide faster diagnosis and more effective personalized treatment options, including relapses. This service offers greater accessibility to life-changing genomic testing and treatment.
Dr. Hideyuki Saya, Director and Professor of Fujita Cancer Center, said, "I am very excited that the Tumor Portrait™ will be available at Fujita Health University for the first time in Japan. This is expected to not only benefit patients but also have a positive impact on cancer research." Dr. Tamotsu Sudo, a Professor at Fujita Health University and Director of the Department of Cancer Genomics, said, "With Fujita Health University's introduction of a cancer gene panel test, which can also predict the efficacy of immune checkpoint inhibitors, it is expected that the most effective treatment can be selected for patients, minimizing unnecessary treatments and side effects."
“We are proud to partner with Fujita Health University and Haneda Clinic to make the BostonGene Tumor Portrait™ test accessible to more cancer patients in Japan. This collaboration represents a significant step in advancing precision medicine and ensuring that more patients can benefit from tailored therapies that improve outcomes and enhance quality of life,” said Yukimasa Shiotsu, PhD, President of BostonGene Japan.
About Fujita Health University Hospital
Fujita Health University is one of the top universities in Japan. As one of the largest medical facilities with 1,376 beds and 13,500 surgery performances per year, it provides a wide range of advanced medical care. (Toyoake City, Aichi) The university hospital has been designated as an “Area Cancer Medical Treatment Cooperation Base Hospital (High Level)”. It is the only hospital in the prefecture and one of only 14 hospitals in Japan to receive this designation. In the hospital, treatment plans utilize surgical treatment, radiological treatment, internal medical treatment and chemotherapy treatment. For more information, visit https://www.fujita-hu.ac.jp/en/ .
About Fujita Health University Haneda Clinic
Fujita Health University Haneda Clinic was opened on October 2023. Founded as a core of medical research in Haneda, where the forefront of modern science converges, Fujita Medical Innovation Center Tokyo takes on challenges in cancer genomics, regenerative medicine, advanced reproductive healthcare, precision rehabilitation, and more. Leveraging these resources to the fullest is the goal of Fujita Health University Haneda Clinic, dedicated to private healthcare. For more information, visit: https://haneda.fujita-hu.ac.jp/en/activity/
About BostonGene Corporation
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com .
About BostonGene Japan
BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022832759/en/
Source: BostonGene
Business Wire
- 10/22 11:30 Fujita Health University and BostonGene Expand Access to Genomic Cance...
- 10/22 02:10 Mitsubishi Electric, ME Innovation Fund Invests in Formic Technologies...
- 10/21 15:00 Giant Manga Publisher Kodansha Launches Official App “K MANGA” in ...
- 10/21 12:30 DigitalBridge to Take JTOWER Private, Acquires Majority Stake
- 10/21 12:06 Arthur D. Little Appoints 9 New Partners Across Global Offices
- 10/21 08:00 Kioxia to Unveil Emerging Memory Technologies at IEDM 2024
- 10/18 10:43 CORRECTING and REPLACING Kioxia Demonstrates Flexible Data Placement-E...
- 10/18 05:02 Toyoda Gosei Increases Rubber Recycling Capacity Towards Decarbonized,...
- 10/18 01:00 Kyocera Document Solutions - Fashion brand ANREALAGE announced a colla...
- 10/17 18:48 US Navy Names Navy Federal Branch “Credit Union of the Year”
- 10/17 11:15 NEXiCONN AI Pixel-Plus CaptureX NV601/NV501 Brings a New Era of 4K Ult...
- 10/17 03:00 FPT Software's Multi-Million Dollar Investment in Employee Learning an...
- 10/17 02:00 JATCO Drives into the Future with the AI-Native Networking Platform fr...
- 10/17 02:00 Talendy Holdings in Singapore to Expand Asia-Pacific Operations
- 10/16 16:00 JCR Pharmaceuticals to Present at the European Society of Gene and Cel...
- 10/16 12:15 EQT-backed Indium Acquires Majority Stake in Experion, a Global Produc...
- 10/16 12:00 Renesas Introduces Four-Channel Master IC and Sensor Signal Conditione...
- 10/16 12:00 IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Stud...
- 10/16 09:45 Takayuki Ito Elected President of The International Federation of Robo...
- 10/16 09:15 Disney Pixel RPG Topped 1 Million Downloads Worldwide in just 7 Days S...
- 10/16 06:53 CORRECTING and REPLACING Kioxia Introduces PCIe 5.0 NVMe EDSFF E1.S SS...
- 10/16 05:00 “IDEMITSU IFG Plantech Racing” was adopted for use in the “MAZDA...
- 10/16 02:00 AGC Launches the METEORWAVE® ELL Series of Ultra-Low Transmission Los...
- 10/15 23:00 Lenovo Announces Comprehensive New Hybrid AI Portfolio at Global Tech ...
- 10/15 20:43 FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic...
- 10/15 17:01 NAMSA and TERUMO Announce Strategic Outsourcing Partnership
- 10/15 14:00 First Anniversary Special Menu Offering at Sushi Kadan
- 10/15 09:30 Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpult...
- 10/15 09:23 Toyoda Gosei Starts Operations at Airbag Plant in Northern India
- 10/15 08:30 Chiaki Mukai and Masanori Sugiyama Appointed as External Directors of ...